Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy.’ The study aims to evaluate the efficacy of tarlatamab compared to a placebo, focusing on progression-free survival in patients with LS-SCLC.
The intervention being tested is tarlatamab, an experimental drug administered via intravenous infusion. It is designed to improve outcomes for patients who have completed chemoradiotherapy without disease progression.
This study is interventional, with participants randomly assigned to receive either tarlatamab or a placebo. It follows a parallel intervention model with double masking, meaning both participants and investigators are unaware of the treatment allocations. The primary goal is treatment-focused.
The study began on February 20, 2024, and is currently recruiting participants. The last update was submitted on July 30, 2025. These dates are crucial for tracking the study’s progress and potential market impact.
Amgen’s stock performance could be influenced by the outcomes of this study, as positive results may enhance investor confidence and competitive positioning in the oncology market. The study’s progress is crucial for stakeholders monitoring advancements in cancer treatment options.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.